BeiGene | Study Investigating Safety, Tolerability, Pharmacokinetics（PK） and Antitumor Activities of Anti-PD-1(Programmed Death-1) Monoclonal Antibody

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Beigene Study ID

BGB-A317-102

ClinicalTrials.gov ID

NCT04068519

Sex: All

Age: 18 Years / N/A

Study Protocol Statistical Analysis Plan

Sex: All

Age: 18 Years / N/A

Study Protocol Statistical Analysis Plan